NCT04128423View on ClinicalTrials.gov

Study of AMV564 in Subjects With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

December 15, 2021

Study Completion Date

December 31, 2021

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
BIOLOGICAL

AMV564

AMV564 will be administered daily

Trial Locations (11)

22908

University of Virginia, Charlottesville

23601

Peninsula Cancer Institute, Newport News

27710

Duke University Medical Center, Durham

32803

Advent Health, Orlando

33612

Moffitt Cancer Center, Tampa

43202

The Ohio State University, Columbus

45255

The Christ Hospital, Cincinnati

60611

Northwestern University, Chicago

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

90095

UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Amphivena Therapeutics, Inc.

INDUSTRY

NCT04128423 - Study of AMV564 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter